XNASITRM
Market cap48mUSD
Dec 23, Last price
1.78USD
1D
0.56%
1Q
60.36%
IPO
-99.03%
Name
Iterum Therapeutics PLC
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
86.00%
Rev. gr., 5y
-57.19%
Revenues
0k
Net income
-38m
L-13.64%
CFO
-39m
L+112.91%
Earnings
Jun 19, 2025
Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 49,218 | 32,183 | 26,641 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (49,218) | (32,183) | (26,641) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 613 | 301 | 705 | |||||
Tax Rate | ||||||||
NOPAT | (49,831) | (32,484) | (27,346) | |||||
Net income | (38,371) -13.64% | (44,434) -51.47% | (91,564) 76.06% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 1,034 | 433 | 89,643 | |||||
BB yield | -4.05% | -4.21% | -9.34% | |||||
| Debt | ||||||||
Debt current | 332 | 1,627 | ||||||
Long-term debt | 19,144 | 29,770 | 28,334 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 188 | 10,172 | 10,319 | |||||
Net debt | (4,786) | (30,701) | (51,447) | |||||
| Cash flow | ||||||||
Cash from operating activities | (39,330) | (18,473) | (15,842) | |||||
CAPEX | (13) | (62) | (61) | |||||
Cash from investing activities | 23,336 | 13,957 | (54,595) | |||||
Cash from financing activities | 1,034 | (1,818) | 83,127 | |||||
FCF | (50,226) | (32,598) | (34,885) | |||||
| Balance | ||||||||
Cash | 23,930 | 60,838 | 81,344 | |||||
Long term investments | (35) | 64 | ||||||
Excess cash | 23,930 | 60,803 | 81,408 | |||||
Stockholders' equity | (461,162) | (423,151) | (376,666) | |||||
Invested Capital | 473,903 | 490,120 | 463,523 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 12,962 | 12,237 | 163,368 | |||||
Price | 1.97 134.52% | 0.84 -85.71% | 5.88 -60.38% | |||||
Market cap | 25,536 148.43% | 10,279 -98.93% | 960,112 169.55% | |||||
EV | 20,750 | (20,422) | 908,665 | |||||
EBITDA | (47,468) | (30,383) | (24,537) | |||||
EV/EBITDA | 0.67 | |||||||
Interest | 2,361 | 5,553 | ||||||
Interest/NOPBT | ||||||||